Leaderboard
Insiders and issuers ranked by realized signed return on open-market Form 4 trades. Returns are signed: a sale followed by a rally counts against the seller.
What the metrics mean
Return - the insider's signed return per trade, averaged. A +10% stock move on a buy scores +10%; on a sell, -10%. Because most insider activity is concentrated at rallying stocks, this metric correlates with raw stock performance and doesn't fully isolate timing skill from market drift.
Edge - signed return minus the stock's average forward N-day return over the same period. An insider with +5% edge consistently chose better days to trade than someone who'd picked a random day in the same window. Isolates timing skill from "the stock just went up."
Neither metric is the same as ranking stocks by raw return - that would just surface the best-performing tickers, which you can get from any market screener.
Insiders ranked
365
Showing 50 of 365
Quality filters
10+ trades
≥3 issuers, 50% price coverage
Window
5y trailing
Trade date filter
| # | Insider | Trades | Issuers | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|---|
| 1 | Hrt Financial LP | 22/29 | 16 | 95% | +59.5% | +68.9% | +96.7% | -3.7% |
| 2 | Ubs Group AG | 30/31 | 3 | 70% | +28.3% | +1.2% | +71.5% | -1.0% |
| 3 | Brookfield US Inc. | 66 | 4 | 91% | +24.4% | +27.9% | +35.3% | -11.2% |
| 4 | Baker Bros. Advisors LP | 10/18 | 3 | 80% | +24.3% | +14.3% | +50.6% | -0.1% |
| 5 | Baker Felix | 10/18 | 3 | 80% | +24.3% | +14.3% | +50.6% | -0.1% |
| 6 | Baker Julian | 10/18 | 3 | 80% | +24.3% | +14.3% | +50.6% | -0.1% |
| 7 | Baker Bros. Advisors (Gp) LLC | 10/18 | 3 | 80% | +24.3% | +14.3% | +50.6% | -0.1% |
| 8 | Scilex Holding Co | 15 | 3 | 73% | +23.3% | +26.7% | +68.0% | -34.6% |
| 9 | Pakianathan Deepika | 21 | 3 | 100% | +22.0% | +17.6% | +80.5% | +9.3% |
| 10 | Gadicke Ansbert | 31/38 | 4 | 87% | +21.9% | +26.4% | +42.2% | -16.4% |
| 11 | Mpm Asset Management Investors Bv2014 LLC | 31/37 | 3 | 87% | +21.9% | +26.4% | +42.2% | -16.4% |
| 12 | Mpm Bioventures 2014 (B), L.P. | 31/37 | 3 | 87% | +21.9% | +26.4% | +42.2% | -16.4% |
| 13 | Mpm Bioventures 2014 Gp LLC | 31/37 | 3 | 87% | +21.9% | +26.4% | +42.2% | -16.4% |
| 14 | Mpm Bioventures 2014 LLC | 31/37 | 3 | 87% | +21.9% | +26.4% | +42.2% | -16.4% |
| 15 | Mpm Bioventures 2014, L.P. | 31/37 | 3 | 87% | +21.9% | +26.4% | +42.2% | -16.4% |
| 16 | Pacific Investment Management Co LLC | 27 | 3 | 81% | +21.4% | +10.9% | +60.7% | -20.9% |
| 17 | Broad Street Principal Investments, L.L.C. | 16/22 | 5 | 81% | +21.0% | +26.1% | +44.0% | -17.8% |
| 18 | Brookfield Corp /On/ | 84/90 | 6 | 82% | +19.1% | +27.5% | +35.3% | -11.2% |
| 19 | Prime Movers Lab Fund I LP | 112/122 | 3 | 80% | +18.3% | +29.0% | +74.6% | -74.0% |
| 20 | Sloss Dakin | 112/122 | 3 | 80% | +18.3% | +29.0% | +74.6% | -74.0% |
| 21 | Evnin Luke | 64/87 | 4 | 73% | +18.0% | +25.4% | +49.0% | -20.0% |
| 22 | Kolchinsky Peter | 96/102 | 6 | 51% | +17.7% | +0.7% | +75.3% | -13.2% |
| 23 | Ra Capital Management, L.P. | 96/102 | 6 | 51% | +17.7% | +0.7% | +75.3% | -13.2% |
| 24 | Ra Capital Healthcare Fund LP | 96/102 | 6 | 51% | +17.7% | +0.7% | +75.3% | -13.2% |
| 25 | Shah Rajeev M. | 96/102 | 6 | 51% | +17.7% | +0.7% | +75.3% | -13.2% |
| 26 | Magnetar Capital Partners LP | 1,578/1,738 | 4 | 75% | +17.6% | +13.9% | +57.0% | -42.8% |
| 27 | Magnetar Financial LLC | 1,578/1,738 | 4 | 75% | +17.6% | +13.9% | +57.0% | -42.8% |
| 28 | Snyderman David J. | 1,578/1,728 | 3 | 75% | +17.6% | +13.9% | +57.0% | -42.8% |
| 29 | Supernova Management LLC | 1,578/1,738 | 4 | 75% | +17.6% | +13.9% | +57.0% | -42.8% |
| 30 | Ault Milton C III | 47/48 | 3 | 74% | +17.4% | +19.1% | +50.0% | -10.0% |
| 31 | Rocklage Scott M | 26/32 | 5 | 81% | +17.2% | +23.4% | +42.3% | -26.1% |
| 32 | 5am Opportunities I (Gp), LLC | 19/29 | 5 | 84% | +16.6% | +17.3% | +42.3% | -26.1% |
| 33 | 5am Opportunities I, L.P. | 19/29 | 5 | 84% | +16.6% | +17.3% | +42.3% | -26.1% |
| 34 | Parmar Kush | 30/34 | 4 | 77% | +16.5% | +23.4% | +42.3% | -26.1% |
| 35 | Schwab Andrew J. | 30/40 | 6 | 77% | +16.5% | +23.4% | +42.3% | -26.1% |
| 36 | Orbimed Capital Gp VI LLC | 65/83 | 9 | 66% | +16.3% | +21.7% | +53.5% | -30.5% |
| 37 | Alphabet Inc. | 186/189 | 5 | 88% | +15.6% | +19.8% | +59.8% | -19.5% |
| 38 | Fmr LLC | 14/24 | 4 | 71% | +15.3% | +30.5% | +31.2% | -15.4% |
| 39 | Plp Funds Master Fund LP | 14 | 5 | 93% | +15.3% | +17.7% | +29.6% | -32.8% |
| 40 | Diekman John D | 11/17 | 4 | 64% | +14.8% | +31.8% | +32.4% | -18.2% |
| 41 | Gordon Carl L | 10 | 4 | 70% | +14.2% | +30.7% | +35.0% | -26.4% |
| 42 | Deerfield Management Company, L.P. (Series C) | 25 | 4 | 92% | +13.4% | +10.5% | +29.8% | -0.8% |
| 43 | Deerfield Mgmt IV, L.P. | 25 | 4 | 92% | +13.4% | +10.5% | +29.8% | -0.8% |
| 44 | Deerfield Private Design Fund IV, L.P. | 25 | 4 | 92% | +13.4% | +10.5% | +29.8% | -0.8% |
| 45 | Flynn James E | 25 | 4 | 92% | +13.4% | +10.5% | +29.8% | -0.8% |
| 46 | McGuire Terrance | 19 | 4 | 84% | +12.9% | +13.6% | +34.5% | -22.2% |
| 47 | Biotechnology Value Fund II LP | 12/21 | 5 | 100% | +12.7% | +12.0% | +16.1% | +10.1% |
| 48 | Biotechnology Value Fund L P | 12/21 | 5 | 100% | +12.7% | +12.0% | +16.1% | +10.1% |
| 49 | Bvf Gp Holdings LLC | 12/21 | 5 | 100% | +12.7% | +12.0% | +16.1% | +10.1% |
| 50 | Bvf I Gp LLC | 12/21 | 5 | 100% | +12.7% | +12.0% | +16.1% | +10.1% |
Showing 1-50 of 365